((自动化翻译由路透提供，请见免责声明 ))
10月11日 - ** 药物开发商Molecular Templates 股价在延时交易中下跌约21%至1.16美元
** 周五晚些时候，MTEM称其董事会批准了清算和解散计划
** 称公司将继续寻求战略替代方案和潜在的资金来源
** 公司表示，目前预计其股东不会因解散而获得有价值的普通股股票
** MTEM 计划结束其两种实验性癌症药物 MT-6402 和 MT-8421 的早期研究
** 董事会批准裁减除管理层主要成员以外的公司大部分员工
** 截至上周五收盘，股价累计下跌约 61
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.